Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Look for This Early in Allogeneic HSCT Patients
Am J Hematol; ePub 2016 Jul 14; Modi, Jang, et al
Pleural effusion is a frequently occurring complication after allogeneic hematopoietic stem cell transplantation (HSCT), according to a retrospective analysis involving 618 individuals.
All participants received allogenic HSCT at a single institution between 2008 and 2013. Among the results:
• 71 patients developed pleural effusion at a median of 40 days after HSCT.
• Cumulative incidence was ~10% at 1 year.
• Infectious etiology, volume overload and serositis type chronic GVHD were linked with pleural effusions.
• Multivariate analysis revealed that higher comorbidity and active GVHD independently predicted pleural effusion development.
• Higher comorbidity index, very high disease risk index, ≤7/8 HLA matching, and unrelated donor negatively impacted overall survival.
The authors noted the importance of identifying these individuals as early as possible.
Citation: Modi D, Jang H, Kim S, et al. Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation. [Published online ahead of print July 14, 2016]. Am J Hematol. doi:10.1002/ajh.24435.